Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
74 results about "Inflammatory arthritis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inflammatory arthritis is a group of diseases which includes: rheumatoid arthritis, psoriatic arthropathy, inflammatory bowel disease, adult-onset Still's disease, scleroderma, juvenile idiopathic arthritis, and systemic lupus erythematosus (SLE).
Ankle prosthesis and method for implanting ankle prosthesis
One embodiment of the present invention relates to an ankle prosthesis. Another embodiment of the present invention relates to a total ankle replacement prosthesis. Another embodiment of the present invention relates to an ankle replacement (partial or total) which is adapted, for example: (a) to treat arthritis of the ankle (e.g., ankle arthritis of any cause: after precious trauma; primary; malalignment induced; after hindfoot fusion; from recurrent ankle instability; rheumatoid or inflammatory arthritis; gout; local growth; dysplasia; growth plate arrest; avascular necrosis; hemophilia; distant septic event); (b) to revise a fused ankle; and / or (c) to treat trauma. The ankle replacement may be carried out by replacing one or more joint surfaces of an ankle joint. Another embodiment of the present invention relates to a method for inserting an ankle prosthesis.
Owner:UNIV OF IOWA RES FOUND
Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
ActiveUS6979679B2Easy to produceReduce presenceBiocideSkeletal disorderWhole bodyInflammatory arthropathy
Owner:ARTHRODYNAMIC HLDG LLC
Composition and method for treatment of joint damage
ActiveUS7485629B2Facilitating nutrient transferPromote regenerationBiocideCarbohydrate active ingredientsWhole bodyInflammatory arthropathy
The invention provides compositions useful for the treatment and / or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and / or parenteral use in the treatment and / or prevention of traumaticsynovitis and / or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and / or prevention of inflammatory arthritis, osteoarthritis (OA) and / or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and / or systemic administration comprised of therapeutic amounts of: chondroitin sulfate and hyaluronan (hyaluronic acid) are provided.
Owner:ARTHRODYNAMIC HLDG LLC
Polymorphs of an androgen receptor modulator
InactiveUS20070129548A1Maintain good propertiesEasy to processOrganic active ingredientsSkeletal disorderDiseaseAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Methods of treating rheumatoid arthritis using il-17 antagonists
ActiveUS20130209480A1Inhibitory activityRapid improvement of clinical manifestationOrganic active ingredientsAntipyreticSecukinumabAntigen
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Owner:NOVARTIS AG
Alpha v integrin receptor antagonists
The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and / or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.
Owner:MERCK SHARP & DOHME CORP
Medicament for treating inflammatory and non-inflammatory arthritis
A medicament for the treatment of inflammatory and non-inflammatory arthritis that includes the following ingredients: arnica, calendula, glucosamine, salicylic acid, hamamelis, emu oil and wild yam. The medicament may be in the form of an ointment, cream, gel, emulsion or liquid solution that is topically applied directly to the affected area. Alternatively, a pad saturated with the medicament having self adhesive qualities that may be placed directly on the affected area may be used. Additionally, the medicament may be applied directly on the affected area or a pad saturated with the medicament is applied to the affected area, and then the area is wrapped with a sleeve or band.
Owner:MALLOZZI OTTAVIO SR +1
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
InactiveUS20060287349A1Minimal effectReduce decreaseBiocideNervous disorderAutoimmune conditionAging skins
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Method for blocking ligation of the receptor for advanced glycation end-products (RAGE)
InactiveUS20090036405A1Less riskReduced anticoagulant activityOrganic active ingredientsSenses disorderDiseaseSulfated polysaccharides
A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis.
Owner:UNIV OF UTAH RES FOUND
17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
A3AR agonists for the treatment of inflammatory arthritis
ActiveUS20040167094A1Effective treatmentReduce riskBiocideSugar derivativesAdenosineInflammatory arthropathy
The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (CL-IB-MECA).
Owner:CAN-FITE BIOPHARMA LTD
A3AR agonists for the treatment of inflammatory arthritis
ActiveUS7141553B2Relieve symptomsEffective treatmentBiocideSugar derivativesAdenosineInflammatory arthropathy
The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5′-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyl-uronamide (CL-IB-MECA).
Owner:CAN-FITE BIOPHARMA LTD
Method of treating inflammatory arthritis
Owner:NATROGEN THERAPEUTICS INT
Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
ActiveUS20060135470A1Easy to produceReduce presenceBiocideCarbohydrate active ingredientsWhole bodyInflammatory arthropathy
The invention provides compositions useful for the treatment and / or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and / or parenteral use in the treatment and / or prevention of traumaticsynovitis and / or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and / or prevention of inflammatory arthritis, osteoarthritis (OA) and / or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and / or systemic administration comprised of therapeutic amounts of: chondroitin sulfate and hyaluronan (hyaluronic acid) are provided.
Owner:ARTHRODYNAMIC HLDG LLC
Indoline compounds for treatment and/or prevention of inflammation diseases
InactiveUS20150368195A1Inhibit release of cytokineBiocideOrganic chemistryInflammatory arthropathyFibrosis
The invention is based on the discovery that 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines and 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles has great potential as a novel agent to be used in the treatment of inflammation-associated diseases, particularly, inflammatory arthritis and fibrosis.
Owner:TAIPEI MEDICAL UNIV
Use of TF antagonists
InactiveUS20060034846A1Reduces TF productionUseful in treatmentCompound screeningApoptosis detectionTissue factorMammalian tissue
Methods of inducing, promoting, and / or enhancing one or more physiological responses associated with the treatment and / or prevention of inflammatory arthritides and / or other inflammation-related conditions in mammals and / or mammalian tissues including delivery of an effective amount of at least one tissue factor antagonist, at least one tissue factor inhibitor, or a combination thereof to a mammal and / or mammalian tissue under conditions such that such a physiological response is induced, promoted, and / or enhanced.
Owner:NOVO NORDISK AS
4-azasteroid derivatives as androgen receptor modulators
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:WANG JIABING +1
Compositions and methods for the treatment of inflammatory bowel disease
ActiveUS20160120839A1Treat and prevent and ameliorate effectBiocideOrganic chemistryEnantiomerUlcerative colitis
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.
Owner:CELLIXBIO PTE LTD
Preparation and use of OPG-HSP70 fusion protein
InactiveCN101434656AInhibition of bone destructionInhibit inflammationPeptide/protein ingredientsSkeletal disorderOsteoblastInflammatory arthropathy
The invention relates to 'a preparation method of OPG-HSP70 fusion protein and an application thereof', pertaining to the new technology field of biological medicaments. The preparation method provides an OPG-HSP70 fusion protein (osteoprotegerin-heat shock protein 70) medicament. According to the most significant pathological features of the rheumatoid arthritis (RA) i.e. the arthrosynovitis with cartilage and bone destruction, the medicament uses the osteoprotegerin as the decoy receptor to combine with the receptor activator of nuclear factor-kB ligand (RANKL) of the nuclear factor kB expressed by osteoblast and other cells, and to interrupt the combination between the RANKL and the RANK expressed by the osteoclast so as to inhibit the bone resorption involved by the osteoclast; and the medicament uses the protective polypeptide segments of the heat shock protein (HSP) to inhibit the inflammatory arthritis. The method contains the DNA sequence which encodes the fusion protein, the method for generating the fusing protein by the recombinant technology, the biological activity of the fusion protein and the like.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Curing and preventing method
InactiveCN1691889APeptide/protein ingredientsAntipyreticInflammatory arthropathyProinflammatory cytokine
The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases. The present invention further provides pharmaceutical compositions comprising agents which inhibit one or more inflammatory cytokines and / or which down-regulate expression of genes which encode inflammatory cytokines. Such compositions are useful in the treatment and prophylaxis of inflammatory conditions such as inflammatory arthritis amongst other chronic immune-mediated inflammatory diseases. The present invention further provides an animal model for studying the kinetics of and / or screening for agents useful in the treatment or prophylaxis of inflammatory conditions.
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES
21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
Owner:MERCK SHARP & DOHME CORP
17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
InactiveUS20080125399A1Minimal effectReduce decreaseBiocideNervous disorderAutoimmune conditionGlucocorticoid
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
InactiveUS20080175845A1Good effectPeptide/protein ingredientsAntibody mimetics/scaffoldsNucleotideInflammatory arthropathy
The present invention provides methods for treating inflammatory arthritis in an individual, comprising administering to the individual an effective amount of AAV (rAAV) vector comprising a polynucleotide encoding a pro-inflammatory cytokine antagonist, wherein the individual is being treated systemically with a polypeptide pro-inflammatory antagonist but still has one or more persistently symptomatic joints.
Owner:TARGETED GENETICS CORPORTION
N-(Pyridin-3-Yl)-2-Phenylbutanamides As Androgen Receptor Modulators
InactiveUS20080124402A1Minimal effectReduce decreaseOrganic active ingredientsPeptide/protein ingredientsDiseaseAging skins
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
Owner:MERCK SHARP & DOHME CORP
il-17a conjugates and uses thereof
Provided is an antibody that specifically recognizes IL-17A and can bind to IL-17A. It can be used to treat inflammatory and autoimmune diseases caused by high expression of interleukin-17A, including psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, inflammatory arthritis, etc.
Owner:SHANGHAI HENGRUI PHARM CO LTD +1
Compositions and methods for treating inflammatory arthritis
ActiveUS20100291234A1Reduce the overall heightLower Level RequirementsOrganic active ingredientsHeavy metal active ingredientsEmulsionOral medication
Methods for treating or preventing one or more symptoms of rheumatoid arthritis or other types of inflammatory arthritis involves administering a formulation containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide formulation can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule.
Owner:THE UNIVERSITY OF HONG KONG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com